Testosterone Enanthate

The U.S. Army Special Operations Veteran and Tactical Fitness Personality Champions a Non-Invasive Testosterone SolutionRALEIGH, N.C., April 22, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, announces its partnership with John “Shrek” McPhee, widely recognized in tactical and fitness communities as the “Sheriff of Baghdad,” who joins KYZATREX® (testosterone undecanoate) CIII capsules as a patient ambassador. McPhee is known for his strong advocacy of testosterone health and his clear preference for non-invasive treatment options. “This is a great solution, I hate injections. Period,” said McPhee. “Finding KYZATREX means I can be on TRT without sticking myself with a needle or more likely, not being on testosterone at all. It’s effective, easy, and doesn’t screw up my routine.” McPhee, a veteran with extensive experience in active military combat and pistol training—having trained over 15,000 individuals on the use of firearms—is a familiar voice on platforms such as the Joe Rogan and Shawn Ryan podcasts. McPhee has also appeared on the Power Athlete podcast, where he introduces the treatment and how KYZATREX has helped to improve his overall health. Marius Pharmaceuticals applauds individuals who raise awareness about testosterone deficiency, particularly among veterans who often face challenges related to low testosterone. Research indicates that testosterone deficiency is a prevalent concern within veteran communities, highlighting the need for effective and patient-friendly treatment solutions. By joining the KYZATREX ambassador program, McPhee is helping to bring more attention to these important health issues. “Partnering with John ‘Shrek’ McPhee, reinforces our commitment to making testosterone therapy accessible and effective,” said Marius Pharmaceuticals CEO Shalin Shah, adding, “With KYZATREX’s innovative, non-invasive formulation, we’re breaking away from outdated injection-based therapies and offering a more patient-friendly solution.” For more information on the Sheriff of Baghdad please visit the SOB Tactical website linked here. About KYZATREX® (testosterone undecanoate) KYZATREX is a proprietary softgel oral formulation absorbed primarily via the lymphatic system (meaning it is not toxic to the liver) indicated in adult males for conditions associated with a deficiency or absence of endogenous testosterone. The safety and efficacy of KYZATREX was demonstrated in a phase 3, multi-center, open-label, six-month study in 155 hypogonadal males between 18 and 65 years of age with documented hypogonadism, as defined by a below normal serum testosterone level (≤281 ng/dL) and at least one sign or symptom of testosterone deficiency. In the efficacy population (n=139), 88 percent of hypogonadal men treated with KYZATREX achieved a mean plasma total testosterone concentration (Cavg) over 24 hours within the normal range (222-800 ng/dL) on the final pharmacokinetic (PK) visit of the study at Day 90 (primary endpoint). Based on exploratory endpoints, patients who received KYZATREX reported improvements in quality of life, energy/fatigue, erectile function, intercourse satisfaction, and positive mood. The most common side effect reported in ≥2 percent of KYZATREX patients was increased blood pressure (2.6%). The safety and efficacy of KYZATREX in males less than 18 years old have not been established. Please see additional Important Safety Information below, including Boxed Warning for potential increased blood pressure, for KYZATREX or visit www.kyzatrex.com. About Marius Pharmaceuticals Marius Pharmaceuticals strives to better the lives of men and women by focusing on therapies designed for hypogonadism or Testosterone Deficiency. Their vision is to holistically improve metabolic health and mitigate significant unnecessary costs to the global healthcare system. For more information, please visit www.mariuspharma.com. Important Safety Information for KYZATREX® (testosterone undecanoate) Use KYZATREX (testosterone undecanoate) is a prescription drug that is used to treat adult men who have low or no testosterone levels due to certain medical conditions. KYZATREX is a controlled substance (CIII) because it contains testosterone. It is not known if KYZATREX is safe or effective in males younger than 18 years old. Improper use may affect bone growth in children. KYZATREX is not meant for use by women. Important Safety Information for KYZATREX® (testosterone undecanoate) KYZATREX can increase blood pressure, which can increase the risk of having a heart attack or stroke and can increase risk of death due to a heart attack or stroke. Your risk may be greater if you have already had a heart attack or stroke or if you have other risk factors for heart attack or stroke. If your blood pressure increases while on KYZATREX, blood pressure medicines may need to be started. If you are currently taking blood pressure medicines, they may need to be changed or new blood pressure medicines may need to be added to control your blood pressure.If your blood pressure cannot be controlled, KYZATREX may need to be stopped.Your healthcare provider will monitor your blood pressure while you are being treated with KYZATREX. Do not take KYZATREX if you: have breast cancer; have or might have prostate cancer; are a woman who is pregnant (KYZATREX may harm your unborn baby); are allergic to KYZATREX or any of its ingredients; or have low testosterone without certain medical conditions (e.g., do not take KYZATREX if you have low testosterone due to age). Before you take KYZATREX, tell your healthcare provider about all of your medical conditions, including if you: have high blood pressure or are treated for high blood pressure; have a history of diabetes; have heart problems; have high red blood cell count (hematocrit) or high hemoglobin laboratory value; have urinary problems due to an enlarged prostate; have liver or kidney problems; or have problems breathing while you sleep (sleep apnea). Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking KYZATREX with certain other medicines can affect each other. Especially, tell your healthcare provider if you take: insulin; medicines that decrease blood clotting (blood thinners); corticosteroids; or medicines that increase blood pressure, such as some cold medicine and pain medicines. KYZATREX may cause other serious side effects including: Increase in red blood cell count (hematocrit) or hemoglobin, which can increase the risk of blood clots, strokes, and heart attacks. You may need to stop KYZATREX if your red blood cell count increases.If you already have an enlarged prostate, your signs and symptoms may worsen while taking KYZATREX. These may include: increased urination at night; trouble starting your urine stream; urinating many times during the day; urge to go to the bathroom right away; a urine accident; inability to pass urine or weak urine flow.Increased risk of prostate cancer.Blood clots in the legs or lungs. Signs and symptoms of a blood clot in your leg can include pain, swelling or redness. Signs and symptoms of a blood clot in your lungs can include difficulty breathing or chest pain.Abuse. Testosterone can be abused when taken at higher than prescribed doses and when used with other anabolic androgenic steroids. Abuse can cause serious heart and psychological side effects.In large doses, KYZATREX may lower your sperm count.Liver problems. Symptoms of liver problems may include: nausea or vomiting; yellowing of your skin or whites of your eyes; dark urine; pain on the right side of your stomach area (abdominal pain).Swelling of your ankles, feet, or body (edema), with or without heart failure.Enlarged or painful breasts.Breathing problems while you sleep (sleep apnea). Call your healthcare provider right away if you have any of the serious side effects listed above. The most common side effect of KYZATREX is high blood pressure. Other side effects may include headache, joint or back pain, diarrhea, increased red blood cell count, anxiety, constipation, swelling of the legs, and increased prostate specific antigen (PSA) levels. These are not all the possible side effects of KYZATREX. For more information, ask your healthcare provider or pharmacist. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Marius by calling 1-833-949-5040. Keep KYZATREX and all medicines out of the reach of children. See Full Prescribing Information and Medication Guide for KYZATREX. Media Contacts: Lucky Break PR marius@luckybreakpr.com

题图 | Pixabay撰文 | 宋文法睾酮，是主要由睾丸分泌的类固醇激素，是男性体内最重要的雄激素，它在男性生殖系统发育、第二性征形成等方面发挥关键作用。此外，睾酮还对全身多个系统和器官的功能有重要影响。血清总睾酮（TT）水平会随着年龄的增长而降低，但其在减轻生物衰老方面的潜在作用仍不清楚。2025年4月1日，四川大学华西医院的研究人员在《柳叶刀》子刊" eClinicalMedicine "期刊上发表了一篇题为" Dynamics of serum testosterone and biological aging in men：insights from Chinese，American，and British populations "的研究论文。这项研究分析了中国、美国、英国的5个队列，结果显示，较高的血清总睾酮水平与减缓生物衰老相关，在临床意义上，血清总睾酮水平可能是生物衰老的一个合理指标，其管理可能对促进健康衰老和降低年龄相关疾病风险有重要意义。图：论文截图在这项研究中，研究人员分析了分析了中国、美国、英国的5个队列，使用Klemera和Doubal方法生物年龄（KDM-BA）作为生物衰老的指标，分析了血清总睾酮水平与生物衰老加速之间的关系。5个队列包括：中国西部健康与老龄化趋势（WCHAT，2080）、中国西部自然人群队列研究（WCNPCS，2133）、英国生物库（UKB，6058）、美国国家健康与营养检查调查（NHANES，6976）、华西医院机器人辅助根治性前列腺切除术（RARP）队列。对NHANES、WCHAT和WCNPCS队列分析发现，较高的血清总睾酮水平与减缓生物衰老相关，血清总睾酮水平每增加一个单位，生物衰老加速分别减少0.078年（NHANES）、0.015年（WCHAT）和0.010年（WCNPCS）。血清总睾酮与生物衰老的关系（图：论文截图）对UKB队列分析发现，血清总睾酮水平的增加与生物衰老加速的降低显著相关（β：-0.047），表明总睾酮水平的增加有助于减缓衰老。血清总睾酮水平变化与生物衰老的关系（图：论文截图）对RARP队列分析发现，接受雄激素剥夺治疗（ADT）加速生物衰老，在38名接受ADT治疗的前列腺癌患者中，治疗后生物衰老加速平均增加了1.804年，表明ADT可能加速生物衰老。总之，这项研究提供了血清总睾酮水平与生物衰老之间关系的多源证据，表明较高的血清总睾酮水平与减缓生物衰老相关，结果强调了在临床实践中考虑血清总睾酮水平管理的重要性。值得一提的是，较高睾酮水平的人，可能更自私、小气、不慷慨。此前，深圳大学、华南师范大学的研究人员在《美国国家科学院院刊》（PNAS）上发表了一篇题为" Testosterone reduces generosity through cortical and subcortical mechanisms "的研究论文。研究显示，睾酮通过影响大脑神经活动来减少慷慨行为，导致更自私的选择，睾酮通过影响大脑颞顶联合区的活动，以及颞顶联合区与奖励处理区域之间的功能连接来影响慷慨行为。图：论文截图参考文献：https://doi-org.libproxy1.nus.edu.sg/10.1016/j.eclinm.2025.103178https://doi-org.libproxy1.nus.edu.sg/10.1073/pnas.2021745118